288 related articles for article (PubMed ID: 27102921)
1. Baseline CXCL10 and CXCL13 levels are predictive biomarkers for tumor necrosis factor inhibitor therapy in patients with moderate to severe rheumatoid arthritis: a pilot, prospective study.
Han BK; Kuzin I; Gaughan JP; Olsen NJ; Bottaro A
Arthritis Res Ther; 2016 Apr; 18():93. PubMed ID: 27102921
[TBL] [Abstract][Full Text] [Related]
2. Association of CXCL10 and CXCL13 levels with disease activity and cutaneous manifestation in active adult-onset Still's disease.
Han JH; Suh CH; Jung JY; Nam JY; Kwon JE; Yim H; Kim HA
Arthritis Res Ther; 2015 Sep; 17(1):260. PubMed ID: 26385705
[TBL] [Abstract][Full Text] [Related]
3. Potential novel biomarkers of disease activity in rheumatoid arthritis patients: CXCL13, CCL23, transforming growth factor alpha, tumor necrosis factor receptor superfamily member 9, and macrophage colony-stimulating factor.
Rioja I; Hughes FJ; Sharp CH; Warnock LC; Montgomery DS; Akil M; Wilson AG; Binks MH; Dickson MC
Arthritis Rheum; 2008 Aug; 58(8):2257-67. PubMed ID: 18668547
[TBL] [Abstract][Full Text] [Related]
4. The predictive value of serum soluble ICAM-1 and CXCL13 in the therapeutic response to TNF inhibitor in rheumatoid arthritis patients who are refractory to csDMARDs.
Zhao J; Ye X; Zhang Z
Clin Rheumatol; 2020 Sep; 39(9):2573-2581. PubMed ID: 32206975
[TBL] [Abstract][Full Text] [Related]
5. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
6. Identification of CXCL13 as a marker for rheumatoid arthritis outcome using an in silico model of the rheumatic joint.
Meeuwisse CM; van der Linden MP; Rullmann TA; Allaart CF; Nelissen R; Huizinga TW; Garritsen A; Toes RE; van Schaik R; van der Helm-van Mil AH
Arthritis Rheum; 2011 May; 63(5):1265-73. PubMed ID: 21305530
[TBL] [Abstract][Full Text] [Related]
7. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs.
Bugatti S; Manzo A; Benaglio F; Klersy C; Vitolo B; Todoerti M; Sakellariou G; Montecucco C; Caporali R
Arthritis Res Ther; 2012 Feb; 14(1):R34. PubMed ID: 22336440
[TBL] [Abstract][Full Text] [Related]
8. CCL19, a B cell chemokine, is related to the decrease of blood memory B cells and predicts the clinical response to rituximab in patients with rheumatoid arthritis.
Sellam J; Rouanet S; Hendel-Chavez H; Miceli-Richard C; Combe B; Sibilia J; Le Loët X; Tebib J; Jourdan R; Dougados M; Taoufik Y; Mariette X
Arthritis Rheum; 2013 Sep; 65(9):2253-61. PubMed ID: 23740460
[TBL] [Abstract][Full Text] [Related]
9. A multi-biomarker disease activity score tracks clinical response consistently in patients with rheumatoid arthritis treated with different anti-tumor necrosis factor therapies: A retrospective observational study.
Hirata S; Li W; Defranoux N; Cavet G; Bolce R; Yamaoka K; Saito K; Tanaka Y
Mod Rheumatol; 2015 May; 25(3):344-9. PubMed ID: 25295918
[TBL] [Abstract][Full Text] [Related]
10. Levels of CXCL13 and sICAM-1 correlate with disease activity score in patients with rheumatoid arthritis treated with tocilizumab.
Tuckwell K; Gabay C; Sornasse T; Laubender RP; Wang J; Townsend MJ
Adv Rheumatol; 2019 Dec; 59(1):54. PubMed ID: 31801637
[TBL] [Abstract][Full Text] [Related]
11. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
12. Serum interleukin-6 and survivin levels predict clinical response to etanercept treatment in patients with established rheumatoid arthritis.
Shi R; Chen M; Litifu B
Mod Rheumatol; 2018 Jan; 28(1):126-132. PubMed ID: 28657833
[TBL] [Abstract][Full Text] [Related]
13. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
[TBL] [Abstract][Full Text] [Related]
14. Pretreatment Prediction of Individual Rheumatoid Arthritis Patients' Response to Anti-Cytokine Therapy Using Serum Cytokine/Chemokine/Soluble Receptor Biomarkers.
Uno K; Yoshizaki K; Iwahashi M; Yamana J; Yamana S; Tanigawa M; Yagi K
PLoS One; 2015; 10(7):e0132055. PubMed ID: 26176225
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of CXCL10, CXCL11, CXCL12 and CXCL13 chemokines in serum and cerebrospinal fluid in patients with tick borne encephalitis (TBE).
Zajkowska J; Moniuszko-Malinowska A; Pancewicz SA; Muszyńska-Mazur A; Kondrusik M; Grygorczuk S; Swierzbińska-Pijanowska R; Dunaj J; Czupryna P
Adv Med Sci; 2011; 56(2):311-7. PubMed ID: 22008312
[TBL] [Abstract][Full Text] [Related]
16. Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples.
Smith SL; Eyre S; Yarwood A; Hyrich K; Morgan AW; Wilson AG; Isaacs J; ; Plant D; Barton A
Arthritis Res Ther; 2015 Dec; 17():359. PubMed ID: 26667261
[TBL] [Abstract][Full Text] [Related]
17. MRP8/14 serum levels as a strong predictor of response to biological treatments in patients with rheumatoid arthritis.
Choi IY; Gerlag DM; Herenius MJ; Thurlings RM; Wijbrandts CA; Foell D; Vogl T; Roth J; Tak PP; Holzinger D
Ann Rheum Dis; 2015 Mar; 74(3):499-505. PubMed ID: 24297376
[TBL] [Abstract][Full Text] [Related]
18. Increasing levels of circulating Th17 cells and interleukin-17 in rheumatoid arthritis patients with an inadequate response to anti-TNF-α therapy.
Chen DY; Chen YM; Chen HH; Hsieh CW; Lin CC; Lan JL
Arthritis Res Ther; 2011 Jul; 13(4):R126. PubMed ID: 21801431
[TBL] [Abstract][Full Text] [Related]
19. Can baseline serum microRNAs predict response to TNF-alpha inhibitors in rheumatoid arthritis?
Cuppen BV; Rossato M; Fritsch-Stork RD; Concepcion AN; Schenk Y; Bijlsma JW; Radstake TR; Lafeber FP;
Arthritis Res Ther; 2016 Aug; 18(1):189. PubMed ID: 27558398
[TBL] [Abstract][Full Text] [Related]
20. Anti-Ro/SSA antibodies are an independent factor associated with an insufficient response to tumor necrosis factor inhibitors in patients with rheumatoid arthritis.
Matsudaira R; Tamura N; Sekiya F; Ogasawara M; Yamanaka K; Takasaki Y
J Rheumatol; 2011 Nov; 38(11):2346-54. PubMed ID: 21965648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
